Related Experiment Videos
Progression of an iris melanoma over 41 years
1Princess Alexandra Eye Pavilion, Royal Infirmary of Edinburgh.
The British Journal of Ophthalmology
|September 1, 1990
Abstract:
An iris melanoma first recorded in 1945 progressed over a period of 41 years to produce secondary glaucoma resulting in enucleation. The case illustrates the advancing nature of such lesions.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Scleral-fixated intraocular lens implants-evolution of surgical techniques and future developments.
Eye (London, England)·2021
The incidence of unexplained visual loss following removal of silicone oil.
Eye (London, England)·2015
Genome-wide association studies: applications and insights gained in Ophthalmology.
Eye (London, England)·2014
Aggressive retinopathy of prematurity: characteristics and risk factors for retreatment.
The British journal of ophthalmology·2026
Novel insights of minocycline as a neurovascular protective agent in retinitis pigmentosa.
The British journal of ophthalmology·2026
Astigmatism trends in adults of Hong Kong from 2015 to 2024: The Hong Kong Children Eye Study.
The British journal of ophthalmology·2026
Efficacy and safety of ELIOS excimer laser trabeculostomy versus iStent inject as an adjunct to phacoemulsification: a retrospective comparative study.
The British journal of ophthalmology·2026
Variation in cataract surgical outcomes by facility type: evidence from 168 population-based surveys in 61 countries.
The British journal of ophthalmology·2026
Lens attachment guard (LAG): a novel protection system for lenses used in ophthalmology.
The British journal of ophthalmology·2026
Intraoperative Hemodynamic Management and Cerebral Protection During Awake Craniotomy: Evidence-Based Approaches.
Anesthesiology research and practice·2026
Combined Enzyme-Responsive Nano-Peptide Drug with Photothermal Function for Effective Anti-Hepatocellular Carcinoma in Mice Model.
International journal of nanomedicine·2026
Pathologic Complete Response to Neoadjuvant Dual Checkpoint Blockade with Durvalumab Plus Tremelimumab in Advanced-Stage HCC: A Case Report.
Journal of hepatocellular carcinoma·2026